Skip to main content
. 2016 Dec 10;3(1):44–56. doi: 10.1016/j.trci.2016.11.005

Fig. 1.

Fig. 1

Chronic intracerebroventricular (icv) infusions of the amylin receptor antagonist, AC253, improve behavioral performance and spatial memory in TgCRND8 Alzheimer's disease mouse model. (A) Schedule and timeline for behavioral testing and administration of icv AC253. (B1, C1) Data from Morris Water Maze (MWM) testing shows daily escape latencies during platform trials of either wild-type (Wt) or TgCRND8 (Tg) mice receiving icv artificial cerebrospinal fluid (CSF) or AC253 at the age of 3 and 8 months (n = 7 mice in each group; ∗∗∗P < .001 Tg-CSF vs. Tg-AC253). (B2, C2) Probe tests (for retention of platform placement) show comparative analysis of time spent in the four quadrants between treatment groups of Wt and TgCRND8 mice. Target Q, quadrant where the platform is located. (B3, C3) Graph showing the percentage of alteration in T-maze test. (n = 7 mice in each group, ∗P < .05, ∗∗P < .01).